Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer
| Autor: | Pernille Lassen, Lisbeth Juhler Andersen, Elo Andersen, Jørgen Johansen, Claus Kristensen, Jan F. Evensen, Jens Overgaard, Hanne Primdahl, Jesper Grau Eriksen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Oncology Larynx HPV medicine.medical_specialty medicine.medical_treatment Gene Expression p16 HNSCC Disease-Free Survival Cohort Studies Internal medicine medicine Overall survival Humans Radiology Nuclear Medicine and imaging Stage (cooking) Papillomaviridae Cyclin-Dependent Kinase Inhibitor p16 Aged Aged 80 and over Radiotherapy business.industry Pharynx Head and neck cancer Cancer Hematology Middle Aged Prognosis medicine.disease Survival Analysis Neoplasm Proteins Surgery Radiation therapy Oropharyngeal Neoplasms stomatognathic diseases Treatment Outcome medicine.anatomical_structure nervous system Head and Neck Neoplasms Radiology Nuclear Medicine and imaging Cohort Carcinoma Squamous Cell Female business |
| Zdroj: | Lassen, P, Primdahl, H, Johansen, J, Kristensen, C A, Andersen, E, Andersen, L J, Evensen, J F, Eriksen, J G, Overgaard, J & Danish Head and Neck Cancer Group (DAHANCA) 2014, ' Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer ', Radiotherapy & Oncology, vol. 113, no. 3, pp. 310-6 . https://doi.org/10.1016/j.radonc.2014.11.032 Lassen, P, Primdahl, H, Johansen, J, Kristensen, C A, Andersen, E, Andersen, L J, Evensen, J F, Eriksen, J G, Overgaard, J & Danish Head and Neck Cancer Group (DAHANCA) 2014, ' Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer ', Radiotherapy & Oncology, vol. 113, no. 3, pp. 310-316 . https://doi.org/10.1016/j.radonc.2014.11.032 |
| ISSN: | 0167-8140 |
| DOI: | 10.1016/j.radonc.2014.11.032 |
| Popis: | Background and purpose: HPV is found in head and neck cancer from all sites with a higher prevalence in oropharynx cancer (OPC) compared to non-OPC. HPV/p16-status has a significant impact on radiotherapy (RT) outcome in advanced OPC, but less is known about the influence in non-OPC. We analyzed HPVassociated p16-expression in a cohort of patients with stage III–IV pharynx and larynx cancer treated with primary, curatively intended (chemo-)RT, aiming to test the hypothesis that the impact of HPV/ p16 also extends to tumors of non-oropharyngeal origin. Material and methods: 1294 patients enrolled in previously conducted DAHANCA-trials between 1992 and 2012 were identified. Tumors were evaluated by p16-immunohistochemistry and classified as positive in case of staining in >70% of tumors cells. Results: Thirty-eight percent (490/1294) of the tumors were p16-positive with a significantly higher frequency in OPC (425/815) than in non-OPC (65/479), p < .0001. In OPC p16-positivity significantly improved loco-regional control (LRC) (adjusted HR [95% CI]: 0.43 [0.32–0.57]), event-free survival (EFS) (HR 0.44 [0.35–0.56]), and overall survival (OS) (HR: 0.38 [0.29–0.49]), respectively, compared with p16-negativity. In non-OPC no prognostic impact of p16-status was found for either endpoint: LRC (HR: 1.13 [0.75–1.70]), EFS (HR: 1.06 [0.76–1.47]), and OS (HR: 0.82 [0.59–1.16]). Conclusions: The independent influence of HPV-associated p16-expression in advanced OPC treated with primary RT was confirmed. However, RT-outcome in the group of non-OPC did not differ by tumor p16-status, indicating that the prognostic impact may be restricted to OPC only. 2014 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 310–316 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect